Collaboration with NABH for Pharmacovigilance Activities

Indian Pharmacopoeia Commission (IPC) has signed a Memorandum of Understanding (MoU) with National Accreditation Board for Hospitals and Healthcare providers (NABH) on 10th Jan 2017 The objective of this MoU between IPC and NABH is to promote monitoring and reporting of Adverse Drug Reaction (ADR) by NABH accredited Hospitals to Pharmacovigilance Programme of India. Indian Pharmacopoeia Commission is the National Coordination Centre for Pharmacovigilance Programme of India. A Memorandum signing ceremony was organised by IPC at CDSCO Headquarter, FDA Bhawan, New Delhi on 10th Jan 2017.

MoU is being signed by Dr. G. N. Singh, Secretary-cum-Scientific Director, IPC and Dr. B.K. Rana, CEO-incharge, NABH

Dr. G. N. Singh and  Dr. B.K. Rana exchanges the MoU, Dr. R. P. Singh, Secretary General, QCI, Dr. H.S. Rehan,HOD Pharmacology, Lady Hardinge Medical College, New Delhi , Dr. Madhur Gupta, Technical officer, WHO and other delegates were also present on this occasion.

Group Photo after MoU Signing Ceremony at FDA Bhawan.